Bio-link Australia Pty. Ltd.

Platform Technologies
Bio-Link’s portfolio of platform technologies that are available for licensing  and partnership include the following:

Blockmir Technology to Selectively Up Regulate Therapeutic Targets and Neutralise Disease-Associated microRNA Activity

Mirrx Therapeutics A/S is commercialising innovative ”Blockmir” oligonucleotide technology, a proprietary therapeutic paradigm with potential to (i) enhance the protein expression of previously undruggable targets, and (ii) neutralise pathological microRNA expression via selective blockade of microRNA-based gene regulation. Blockmir drugs are differentiated, and expected to be superior to other technologies designed to enhance protein expression or modulate microRNA activity, benefiting from ease of design, promotion of endogenous, physiological and tissue-specific protein expression, attractive pharmacokinetics and formulation. Having generated exciting proof of principle data, Mirrx is now interested to enter into strategic collaborations to design, develop and commercialise Blockmir therapeutic drugs. Summary (PDF)